Beeline Medicines' Afimetoran Hits Primary Endpoint in Global Phase 2 SLE Trial, Advancing to Pivotal Development
核心洞察
Beeline Medicines (搜索) reported positive topline results from its global Phase 2 trial of afimetoran in systemic lupus erythematosus (搜索), with all three dose groups beating placebo on SRI-4 at Week 48.
The study met its primary endpoint with a p-value below 0.001 across all three afimetoran dose groups, and secondary endpoints were consistent with the primary findings.
Afimetoran, an oral once-daily TLR7 (搜索)/8 inhibitor, was generally well tolerated with no new safety signals relative to prior Phase 1 experience.
Beeline Medicines (搜索) Corporation reported positive topline results from its global Phase 2 study of afimetoran in systemic lupus erythematosus (搜索) (SLE), with all three dose groups demonstrating higher SLE Responder Index-4 (SRI-4) response rates at Week 48 compared with placebo (p-value <0.001 across all three dose groups). The trial met its primary endpoint, and secondary endpoints showed improvements consistent with the primary findings, reinforcing the overall efficacy profile.
Afimetoran is an investigational selective, oral, once-daily, equipotent small-molecule inhibitor of Toll-like receptors 7 and 8 (TLR7 (搜索) and TLR8 (搜索)). The company said the safety and tolerability of afimetoran were generally consistent with previous Phase 1 clinical trial experience, and no new safety signals were observed. Detailed results are expected to be presented at an upcoming medical congress.
Trial Design and Population
The Phase 2 study (NCT04895696) is a global, double-blind, randomized, dose-ranging, placebo-controlled trial evaluating the efficacy, safety, and tolerability of afimetoran in 248 adults with active SLE. The trial enrolled adults aged 18 to 70 years with active moderate-to-severe SLE despite ongoing background treatment.
Participants were randomized 1:1:1:1 to receive once-daily oral afimetoran at one of three dose levels or placebo through Week 48, in addition to protocol-permitted background standard of care medications, including corticosteroids with a mandatory corticosteroid taper. The primary endpoint assessed SRI-4 response at Week 48. Secondary endpoints assessed measures of disease activity including low disease activity, skin and joint manifestations, corticosteroid reduction, physician global assessment, and quality of life.
Mechanism and Prior Development
According to the company, TLR7 (搜索) and TLR8 (搜索) play complementary and critical roles in lupus pathogenesis. Human genetics directly implicate TLR7 as a disease driver in lupus, while the biology of TLR8 contributes to pro-inflammatory cytokine production and immune responses, leading to potential progressive disease activity and irreversible organ damage. By blocking these components of the immune cascade, afimetoran rapidly and substantially suppresses signaling pathways in innate immune cells and B cells implicated in the pathology of various autoimmune diseases, including systemic and cutaneous lupus erythematosus (搜索).
Afimetoran was discovered by Bristol Myers Squibb (搜索)'s researchers and was licensed to Beeline Medicines (搜索) in July 2025. It previously demonstrated exploratory efficacy in a Phase 1b study in cutaneous lupus erythematosus (搜索) (CLE) and was granted Fast Track designation by the U.S. Food and Drug Administration for SLE in May 2025.
Company Positions Program for Pivotal Development
"Too many people with systemic lupus continue to cycle through therapies that do not adequately control their disease, leaving them with diminished quality of life and vulnerable to debilitating long-term complications," said Saqib Islam, Chief Executive Officer of Beeline Medicines (搜索). "These positive Phase 2 results strengthen our conviction that afimetoran has the potential to meaningfully change the treatment landscape as a foundational oral therapy for lupus patients. We look forward to advancing our program into pivotal development for those who urgently need new options."
"For people living with lupus, there is a significant need for effective, well-tolerated therapies that fit into everyday life," said Nathalie Franchimont, M.D., Ph.D., Chief Medical Officer of Beeline Medicines (搜索). "Afimetoran's clinically meaningful effects across measures of disease activity in this Phase 2 trial point to its potential to address both systemic and cutaneous manifestations and reinforce our belief in TLR7 (搜索)/8 inhibition as a mechanism uniquely suited to address a central driver of lupus biology."
The company plans to advance afimetoran into pivotal development for both SLE and CLE.
Disease Burden and Unmet Need
Lupus encompasses a spectrum of chronic, heterogeneous autoimmune conditions marked by immune dysregulation, autoantibody production, and inflammation that can affect multiple organ systems. More than 5 million people worldwide live with a form of lupus, which disproportionately affects women of childbearing age — approximately 90% of people living with lupus are women — and individuals of Black, Hispanic, Asian, and Indigenous ancestry, in whom the disease tends to begin earlier, damage organs more rapidly, and lead to worse outcomes.
Its principal forms, including SLE, CLE, and lupus nephritis (搜索) (LN), which reflects renal involvement in SLE, overlap along a continuum. Up to 85% of people with SLE develop cutaneous manifestations, and while up to 25% of patients initially diagnosed with CLE may progress to SLE over time, not all patients presenting with CLE will develop systemic disease.
SLE is the most common form of lupus and includes the most severe manifestations, characterized by multi-organ involvement and a relapsing-improving course of episodic flares that can cause cumulative, irreversible organ damage and significant morbidity. CLE comprises inflammatory skin conditions that can occur alone or alongside systemic disease, with lesions that range from localized to widespread and can lead to profound impact on quality of life and lasting scarring and dyspigmentation in discoid lupus. Despite recent advances, an urgent unmet need remains for well-tolerated, oral targeted therapies that deliver durable disease control with reduced steroid exposure.